Kestra Medical Technologies Ltd is a commercial-stage wearable medical device and digital healthcare company focused on connected monitoring, therapeutic intervention, and data-driven clinical insights for cardiovascular disease. It has developed and is commercializing the Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. The platform is anchored by the ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected. The platform also includes digital patient engagement and clinical workflow solutions.
Last trade$28.44
Day change+$0.47 (+1.68%)
Day range$27.36 – $28.59
Volume132,461
Market cap$1.67B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.67B
Price / earnings
—
Price / book
7.49×
Price / sales
15.61×
EV / sales
15.65×
EV / EBITDA
-12.45×
Profitability
Earnings per share
-$2.52
Return on assets
-43.15%
Return on equity
-67.4%
Dividend yield
0.03%
Liquidity and leverage
Debt / equity
0.33×
Current ratio
4.69×
Quick ratio
4.53×
Cash ratio
1.42×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$122.79M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KMTS, quarterly periods
Line item
Q1 FY2027 Jul 31, 2026
Q4 FY2026 Apr 30, 2026
Q3 FY2026 Jan 31, 2026
Q2 FY2026 Oct 31, 2025
Q1 FY2026 Jul 31, 2025
Q4 FY2025 Apr 30, 2025
Revenue
$30.97M
$28.64M
$24.55M
$22.57M
$19.37M
$17.23M
Cost of revenue
$13.47M
$12.96M
$11.65M
$11.14M
$10.52M
$9.6M
Gross profit
$17.5M
$15.68M
$12.91M
$11.42M
$8.85M
$7.63M
Selling, general and administrative
$48.36M
$49.39M
$42.7M
$38.3M
$33.73M
$50.46M
Research and development
$6.8M
$5.63M
$4.97M
$4.88M
$4M
$5.39M
Total operating expenses
$55.16M
$55.03M
$47.67M
$43.18M
$37.73M
$55.85M
Operating income
-$37.66M
-$39.34M
-$34.77M
-$31.76M
-$28.88M
-$48.21M
Interest expense
-$1.93M
-$1.84M
-$1.89M
-$1.9M
-$1.91M
-$1.76M
Income before taxes
-$44.04M
-$38.64M
-$34.13M
-$32.75M
-$25.79M
-$51.01M
Income taxes
$50K
$192K
$35K
$34K
$33K
$102K
Net income
-$44.09M
-$38.84M
-$34.17M
-$32.79M
-$25.83M
-$51.11M
Net income attributable to common shareholders
-$44.09M
-$38.84M
-$34.17M
-$32.79M
-$25.83M
-$55.34M
EBITDA
-$34.99M
-$37.02M
-$32.78M
-$29.38M
-$26.85M
-$46.38M
Basic earnings per share
-$0.75
-$0.67
-$0.61
-$0.64
-$0.50
-$1.43
Diluted earnings per share
-$0.75
-$0.67
-$0.61
-$0.64
-$0.50
-$1.43
Recent news
Company coverage with links to the original publishers.
Rapid Micro Biosystems reported a Q3 loss of $0.22 per share, missing EPS expectations by 10% despite beating revenue estimates at $9.53 million. The company has underperformed the market significantly, down 77.6% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market.
Rockwell Medical reported a quarterly loss of $0.59 per share, significantly worse than the consensus estimate of $0.18, representing a -227.78% earnings surprise. The company posted revenues of $19.12 million, slightly beating estimates but has underperformed the S&P 500 by 26.4% year-to-date. With a Zacks Rank #3 (Hold) rating and the Medical-Products industry in the bottom 42% of performance, the stock is expected to perform in line with the market.
Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, announced its participation in three upcoming investor conferences in November and December 2026, including the Wolfe Research Healthcare Conference, Stifel Healthcare Conference, and Piper Sandler 38th Annual Healthcare Conference. Live webcasts and replays will be available on the company's investor relations website.
Kestra Medical Technologies reported a Q1 loss of $0.75 per share, missing EPS expectations of $0.61 by 22.95%, though it exceeded revenue estimates with $30.97 million (6.66% above consensus). The company has underperformed the S&P 500 by 25.7% year-to-date and carries a Zacks Rank #3 (Hold) rating, with mixed estimate revisions ahead.
Kestra Medical Technologies announced the appointment of Daniel Finney as Vice President of Research & Development and executive leadership team member. Finney, who has over 20 years of medical device development experience, succeeds Phillip D. Foshee, Jr. and will lead the company's innovation initiatives across the Cardiac Recovery System platform, including AI applications and strategic partnerships.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.